Sells it“In our Discovery Collaboration partnership model, such as our partnerships with AbbVie, Takeda, and Lundbeck, we use our molecular superintelligence platform for the development of drug candidates on specified disease-driving targets.”
Supplies it 2%, $31.0M a quarter“Cost of sales was 24% of net product sales plus stand-ready manufacturing revenue in Q3, versus 21%; for 9M it was 75% versus 34%.”
European COVID deliveries and lower R&D spending restored quarterly profit; mFLUSIVA launched after the main contracting season.
Revenue$1.3BYoY +29.2%
Net income$162.0Mvs −$200.0M year ago
Latest 8-KPositiveDebt financing ·
Credit amendment cuts initial and delayed-draw term-loan margins 75 bp and extends maturity to November 2031.
Latest 8-KLeadership change ·
Chief Legal Officer Klinger to retire March 2027 with $1.63M severance and conditional payouts tied to Arbutus/Genevant and Pfizer/BioNTech litigation.
Sells it“As part of our Cancer Care Continuum strategy, we also plan to expand the number of biopharma partners we serve with services including biomarker identification and validation, companion diagnostic test development and regulatory registration, as well as companion diagnostic test commercialization.”
Sells it 2%, $1.3B a year“PC1 is our contract development and manufacturing organization and a leading supplier of specialty active pharmaceutical ingredients.”
Latest 10-KFY2025Impairment / charge ·
Paxlovid and Comirnaty declines masked non-COVID growth; the Metsera deal targets obesity as patent losses loom.
Revenue$62.6BYoY −1.6%
Net income$7.8BYoY −3.2%
Latest 10-QQ3 FY2026MixedImpairment / charge ·
Eliquis and Padcev gains counter COVID-19 declines, but pipeline write-downs expose risks in replacing aging franchises.
Revenue$16.6BYoY −0.4%
Net income$3.2BYoY −8.4%
Latest 8-KCEO/CFO change ·
Interim CFO Cecile Guegan appointed permanent CFO and EVP, effective Nov. 1.
Sells it 21%, $54.8M a year“We generate drug discovery revenue through the performance of specified research and development activities under our collaboration agreements and upon the achievement of discovery and development milestones”
Latest 10-KFY2025MixedRestructuring ·
Novartis collaboration work and hosted-software sales drove growth, but higher delivery costs squeezed gross margin.
Sells it, part of Service, Laboratory Products and Biopharma Services“Our pharma services business provides the entire spectrum of development, manufacturing and clinical trials services for both small-molecule and large-molecule pharmaceuticals.”
Latest 10-KFY2025Restructuring ·
Solventum filtration purchase and pending Clario deal deepen the push into drug development and production as academic demand and China sales weaken.
Sells it, part of DNA Synthesis And Protein Solutions“Through DNA Synthesis and Protein Solutions, we offer end-to-end solutions for therapeutic drug discovery including DNA synthesis, protein expression, antibody characterization and biologics discovery solutions.”
Latest 10-KFY2026Positive ·
AI-enabled drug discovery lifts DNA Synthesis and Protein Solutions, but commercial hiring and litigation absorb gross-profit gains.
Revenue$459.4MYoY +22.0%
Net income−$130.2MYoY −67.6%
Latest 10-QQ3 FY2026Legal / investigation ·
Synthetic biology and therapeutics demand drove growth, but commercial and infrastructure spending widened operating losses.